CreditAccess Grameen Ltd. moves to reshape its capital structure

The supplied disclosures do not establish the coupon rate or tenor for an INR 215 crore NCD allotment, so its effective cost cannot be calculated reliably.

• The Q1 FY27 results release refers to a private NCD issuance of INR 425 crore, not INR 215 crore, and does not provide its coupon or maturity terms. ^[1]
• Management indicated that FY27 borrowing costs were expected to average approximately 9.3%, with a possible 10–15 basis-point increase from greater use of longer-tenure ECB and NCD funding. ^[2]
• The latest explicitly reported historical cost of borrowing in the supplied earnings-call material is 9.2% for Q4 FY26; this is not the same as a Q1 FY27 WACF disclosure. ^[3]

Accordingly:

A valid comparison would be: effective cost = coupon adjusted for issue discount, upfront fees and other issuance costs, annualised over the NCD tenor. It should then be compared with the same-period WACF, not with the FY27 borrowing-cost expectation or the Q4 FY26 9.2% figure.

The latest disclosure does not support an INR 215 crore issuance. It reports a Rs 425 crore private NCD issuance in Q1 FY27, completed during the quarter and described as a liability-base diversification measure ^[4]. Accordingly, attributing the entire liquidity or ALM change to Rs 215 crore would be incorrect.

Role in FY27 resource mobilisation

CreditAccess Grameen’s FY27 funding requirement is linked to management’s 20–25% AUM-growth guidance; management also said that internal accruals had historically funded a large part of growth ^[3]. The NCD is therefore best viewed as part of a broader shift toward diversified and longer-tenor liabilities rather than as a standalone liquidity event.

• The Q1 disclosure put foreign borrowings at 23.9% of the liability mix and said the Rs 425 crore NCD further diversified funding ^[4].
• Management indicated that the funding mix would increasingly include longer-tenor ECB and NCD borrowings, with an estimated 10–15 basis-point impact on borrowing costs ^[2].
• A subsequent September report also records a separate Rs 300 crore bilateral NCD placement, including 24-month and 36-month tranches, which is consistent with continued tenor diversification during FY27 ^{[5] [6]}. This later transaction was not part of the Q1 liquidity snapshot.

Liquidity and ALM impact

The higher liquidity buffer is a meaningful strengthening of immediate balance-sheet liquidity. However, the filing does not attribute the entire Rs 1,133.2 crore increase specifically to the NCD; cash generation, collections, disbursement timing and other borrowing movements would also affect the period-end balance.

For ALM, longer-tenor NCDs should, directionally, reduce dependence on short-term refinancing and improve liability-tenor matching against a predominantly longer-duration lending book. The disclosed funding mix supports that interpretation, but the latest reported material does not provide the maturity-bucket ALM ladder, cumulative asset-liability mismatches, or tenor-wise liquidity gaps. Therefore, the evidence supports improved funding diversification and a larger liquidity cushion, but not a quantified improvement in the formal ALM gap profile.

The Rs 215 crore tranche is consistent with CreditAccess Grameen’s liability-diversification strategy, but it represents diversification within market-sourced funding—not a reduction in reliance on capital-market debt. The NCDs are senior, secured, rated and proposed to be listed on BSE’s Wholesale Debt Market; they carry a fixed 9.15% coupon for 24 months and are secured by identified receivables at a minimum 1.10x cover. ^{[8] [9]}

What the tranche means

Management explicitly described a Rs 425 crore private NCD issuance during Q1 FY27 as a measure that “further diversifies” the liability base, while foreign borrowings represented 23.9% of liabilities at that time. ^[1] The subsequent Rs 215 crore issue therefore extends an already active funding channel and likely broadens the lender/investor base, tenor profile and refinancing access.

However, the interpretation needs two qualifications:

• It is not diversification away from debt-market funding. Private-placement NCDs are themselves capital-market or market-sourced liabilities. The diversification benefit depends on the investor base being different from the company’s bank, ECB, securitisation and other lenders.
• It is fixed-rate rather than floating-rate market-linked debt. The 9.15% coupon is fixed, so the tranche does not create direct benchmark-rate reset exposure during its 24-month tenor. ^[8]

Using Q1 FY27 consolidated liabilities of Rs 24,088 crore as a pre-issuance reference, the Rs 215 crore tranche equals approximately 0.89% of liabilities (derived from Rs 215 crore / Rs 24,088 crore). ^{[10] [11]} This is the size of the incremental issue, not CreditAccess Grameen’s total market-linked debt proportion.

CreditAccess Grameen versus peers

The currently cited evidence does not provide a source-by-source borrowing split—bank loans, NCDs, ECBs, securitisation, commercial paper or other market-linked liabilities—for CreditAccess Grameen or the peer set. Accordingly, a defensible ranking of market-linked debt shares is not possible.

• CreditAccess Grameen: foreign borrowings were 23.9% of the liability mix in Q1 FY27, but this is not equivalent to market-linked debt; the Rs 215 crore NCD was allotted subsequently on 1 October 2026. ^{[1] [11]}
• Muthoot Microfin: Q1 FY27 standalone liabilities were Rs 9,830.5 crore, but the cited data does not provide the funding-source split or market-linked debt percentage. ^[12]
• Fusion Finance: Q1 FY27 standalone liabilities were Rs 5,838.9 crore, with no cited source-level liability mix. ^[13]
• Satin Creditcare: Q1 FY27 consolidated liabilities were Rs 11,519.2 crore, but no comparable NCD, bank, ECB or securitisation split is provided. ^[14]
• Spandana Sphoorty: Q1 FY27 consolidated liabilities were Rs 4,116.8 crore, without a comparable market-linked debt percentage. ^[15]

Analytical conclusion: CreditAccess Grameen is visibly increasing its use of private NCDs alongside a material foreign-borrowing component, which supports liability diversification by source and tenor. But the available evidence does not establish that its total market-linked debt share is higher or lower than that of large-cap MFI peers. The key missing comparison is each company’s funding mix as a percentage of total borrowings—not total liabilities and not foreign borrowings alone.